Author: @admin

Post

Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018. Graham Lumsden, Chief Executive Officer of Motif Bio, said: “On...

Post

Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

WASHINGTON, June 6, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present data from their clinical and research programs at the American Society for Microbiology’s ASM Microbe 2018 meeting to be held June 7-11 in Atlanta, GA. ASM Microbe showcases the best microbial sciences in the world and provides a one-of-a-kind...

Post

Efficacy of APX001 in Treatment of Candida Endophthalmitis and Hematogenous meningoencephalitis in the Non-neutropenic Rabbit Model

June 11, 2018/by eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg 0 0 eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg eallison2018-06-11 13:29:282018-06-11 13:29:28Efficacy of APX001 in Treatment of Candida Endophthalmitis and Hematogenous meningoencephalitis in the Non-neutropenic Rabbit Model Scroll to top READ FULL TEXT